AFAP1L1

Across TCGA pan-cancer cohorts, AFAP1L1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AFAP1L1 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AFAP1L1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AFAP1L1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, SCLC, and BLCA are the cancer types where AFAP1L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.128	0.695	.002	24	view →
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	18	view →
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →
LUSC	OS	Median	II,III,IV	0.153	0.745	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.889	0.622	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AFAP1L1–HNSC (DFS)

Open the HNSC breakdown →